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Xenopus oocytesGABAρ1 receptors are formed by homopentameric assemblies that gate a chloride ion-channel upon
activation by the neurotransmitter. Very little is known about the structural and functional roles played by
the different domains that form each subunit; but one of them, the fourth transmembrane segment (TM4), is
known to form a hydrophobic bundle together with three other TM segments that are necessary to stabilize
the structure of the receptor. In this study we progressively removed amino acid residues from the C-
terminus of the human GABAρ1 and studied the functional properties of the receptor mutants expressed in
X. laevis oocytes. We found that deletions of up to the last four residues gave rise to receptors that were still
functional, generating currents of 3.92 µA for the wt, 5.75 μA for S479X, 1.82 μA for F478X, 0.52 μA for I477X
and 0.27 μA for S476X when exposed to 5 µM GABA; surprisingly, the mutant with one residue removed
resulted more sensitive to the agonists. Further deletions, up to residue W475, resulted in receptors that did
not gate an ion-channel. In addition, deleting the signal sequence, from R2-A15, in the N-terminus produced
non-functional receptors. This study reveals that GABAρ1 can tolerate removal of several residues that form
the fourth transmembrane segment up to a critical point, signaled by W475, beyond which the mutant
protein is translated but does not form functional receptors. A comparative study is presented of some
electrophysiological and pharmacological properties of the deletion mutants that were able to generate
GABA currents.B.V.Published by Elsevier B.V.1. Introduction
Ligand-gated ion channels (LGIC) play a fundamental role in
neuronal communication and γ-aminobutyric acid (GABA) receptors
are the major inhibitory LGIC in the adult mammalian brain and
retina. Accordingly, GABA receptors are one of the most important
targets for a variety of clinically prescribed therapeutic compounds
[1–3]. Detailed knowledge of the receptor's structure and function
would provide important information for understanding fundamental
aspects of synaptic transmission and neurological disorders, and
would help also to design new therapeutic compounds that target
speciﬁcally the GABA receptor.
The ionotropic GABAρ receptors permeate chloride ions and
modulate presynaptic inhibition at synaptic terminals of the bipolar
neurons of the retina [4]. The three known subunits that form the
receptors (GABAρ1–ρ3) assemble as functional homopentameric com-plexes when expressed in heterologous systems such as the Xenopus
laevis oocytes. GABAρ receptors are insensitive to bicuculline and
desensitize very little, in sharp contrast to classic GABA-A receptors [5,6].
Basic structural characteristics of ionotropic GABA receptors are
shared by other LGIC, such as the nicotinic acetylcholine (nACh), glycine
and serotonin type 3 receptors which form a phylogenetically related
group of proteins with diverse functional properties, and which share
basic structural characteristics [7]. They all form pentameric assemblies
in the membrane, and their individual subunits have a conserved
structure consisting of four transmembrane segments (TM1–TM4,
Fig. 1). The TM2s of each receptor are aligned in such a way that they
form a central ion-permeant channel. In addition, a large extracellular
amino-terminal domain contains the agonist binding site, and the
intracellular loop between TM3 and TM4 is important for proper
targeting of the receptor to the plasma membrane [9].
A combination of chimeric receptors, site-directed mutagenesis
and molecular dynamics has permitted to deﬁne several distinctive
amino acids important for the function of ionotropic GABAρ receptors,
for example, the agonist binding site of the receptor, the structural
gate of the ion-channel as well as other important modulatory sites,
such as the zinc binding site [10–15]. Nevertheless, very little is
known about the functional and structural roles of the residues in the
Fig. 1. Schematic representation of one subunit of hGABA ρ1 and its TM4. A) Four
transmembrane regions (1–4) span the plasma membrane. Positions of the deletion
mutants and sites in which the GFP was fused are indicated by arrows. B) Amino acid
sequence of TM4, threading as predicted by the HMMTOP transmembrane topology
prediction server [8]. Arrows indicate the position of the mutants generated.
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form the TM4.
In this study, we produced deletion mutants of the C-terminus of
the human GABAρ1 receptor and assessed the impact of the deletions
on the electrophysiological properties of the receptors expressed in
Xenopus oocytes. In addition, a deletion mutant of the signal peptide
of the receptor conﬁrmed the essential role of this domain in
addressing the position of the protein in the plasma membrane.
2. Materials and methods
2.1. Deletion mutants
hGABAρ1 was cloned from a human retina cDNA library and
introduced into pcDNA3 (Invitrogen, Carlsbad, CA) [16]. The deletions
were generated with the high ﬁdelity DNA polymerase Deep vent
(New England BioLabs, Ipswich, MA) and consisted of: 1) deletions at
the C-terminus that introduced a translational stop codon (X in Fig. 1
and Table 1) at: a) the beginning of the short extracellular loop, afterTable 1
Summary of mutants constructed.
Construct Description 5 mM GABA current (μA) EC50 (GABA
wt Wild type 3.92 3.4±1
S479X ΔSer479 5.75 2.1±1a
F478X ΔPhe478-Ser479 1.82 5.4±3
I477X ΔIle477-Ser479 0.52 6.4±2
S476X ΔSer476-Ser479 0.27 3000±2
W475X ΔTrp475-Ser479 NC
Y474X ΔTyr474-Ser479 NC
Y474GFP ΔTyr474-Ser479GFP NC
I473X ΔIle473-Ser479 NC
L472X ΔLeu472-Ser479 NC
N471X ΔAsn471-Ser479 NC
I468X ΔIle468-Ser479 NC
A465X ΔAla465-Ser479 NC
A465GFP ΔAla465-Ser479GFP NC
E361X ΔGlu361-Ser479 NC
E361XGFP ΔGlu361-Ser479GFP NC
W349X ΔTrp349-Ser479 NC
M335X ΔMet335-Ser479 NC
M335XGFP ΔTyr335-Ser479GFP NC
ΔL2-A21 ΔLeu2-Ala21 NC
NC, no current; NT, not tested; Ab, antibody.
a Pb0.05 vs. wt (Student's t-test).S334, b) the end of the short extracellular loop, after L348, c) the end
of TM3 after L360; 2) serial amino acid deletions from the C-terminus
S479 to N471, that is located in the middle of TM4. Then, stop codons
were introduced after Y467 and P464, also embedded in TM4. 3)
Deletion of the signal sequence from the second residue L2 to A21,
conserving the ATG corresponding to the ﬁrst M. Some of the
receptors that did not generate GABA currents were tagged with GFP
towards the C-terminus to assess their ability to reach the plasma
membrane (Fig. 1).
cRNAs were synthesized from each deletion mutant using the
mMessage mMachine kit (Ambion, Austin, TX). At least three
independent cRNA preparations from each construct were tested.
2.2. Expression and electrophysiology in frog oocytes
X. laevis frogs were anesthetized with 0.17% 3-aminobenzoic acid
methylester (MS-222) for 20–30 min. The follicles were manually
removed, enzymatically defolliculated (with 0.3 μg/μl collagenase
type I at room temperature for 45 min) and then kept at 16 °C in
Barth's medium: 88 mMNaCl; 1 mMKCl; 0.33 mM Ca(NO)3; 0.41 mM
CaCl2; 0.82 mM MgSO4; 2.4 mM NaHCO3; 5 mM HEPES; pH 7.4,
containing 0.1 mg/ml gentamicin sulfate. The next day, 50 nl of cRNA
of wtGABAρ1 or deletion mutants (1 μg/μl) were injected and
electrophysiological recordings were obtained 3–5 days after
injection.
Membrane currents elicited by the agonists were recorded using the
two-microelectrode voltage-clamp technique [17]. The oocytes were
placed in a 1000 μl chamber, impaled with two microelectrodes ﬁlled
with 3 MKCl (0.5–1.5 MΩ) and clamped usually at−60 and sometimes
at−80 mVwhen the currents were very small or absent. To obtain the
equilibriummembrane potential of transmitter action, current–voltage
relations were constructed by stepping the oocyte's membrane
potential from −60 to −120 and to +40 (in 20 mV steps) in the
absenceor presence ofGABA,β-alanine (β-ala), taurine (Tau), or glycine
(Gly). All recordings were made at room temperature (20–23 °C) in a
chamber continually perfused (5–10ml/min) with Ringers solution
(115 mM NaCl; 2 mM KCl; 1.8 mM CaCl2; 5 mM HEPES; pH 7.4).
2.3. Drugs and statistics
All drugs were purchased from Sigma (St. Louis, MO) except MS-
222 which was purchased from Argent Chemical Laboratories) Hill no. (GABA) Fluorescence (GFP) Detected by external Ab
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1 M) were stored frozen. All the perfused solutions were at pH 7.0.
Membrane currents are expressed as percentages of the control
responses obtained with GABA alone. Control GABA responses were
obtained before and after each test drug application to account for
possible shifts in the control current amplitude. The data are
expressed as means±SEM. Dose–response relationships were ﬁtted
with the Hill equation: R/Rmax=[C]η/{[C]η+(EC50)η}, where R is the
current elicited by the drug at concentration [C]; Rmax=maximum
response at saturation; η=Hill coefﬁcient; and EC50 (or IC50 in the
case of an inhibitory effect), is the concentration at which half-
maximum response is obtained. Data from each experiment were
collected from at least 12 oocytes, and the kinetics of GABA, β-ala, Gly
or Tau activation (τo) or deactivation (τc) responses, were ﬁt using
Origin 6.0 software (Northampton, MA) to a second-order exponen-
tial decay function of the form: It=Ae−t /τ1+Be−t /τ2, where It is the
current recorded at time t, A and B are the amplitudes of each decay
component at t=0, and τ1 and τ2 are the time constants of each
phase of the current decline towards its asymptotic value. Experi-
mental data are shown as mean±SEM. Differences between two
groups were statistically analyzed with the Student's t-test.2.4. Immunolocalization and ﬂuorescence microscopy
Two to three days after RNA injection, oocytes were scored for
expression of the receptor(s) tagged with GFP. A Carl Zeiss LSM Meta
510 was used with the ﬁlter BP 505–530, wave length 488 (for GFP)
and LP 560, wave length 543 (for Alexa Fluor 568). For immunoﬂu-
orescence, oocytes were labeled with anti-GABAρ1 antibodies toFig. 2. Expression of receptors in oocytes. A–C) No major differences in GFP ﬂuorescence w
ρ1M335X were immunolabeled with antibody coupled to Alexa Fluor 568, also showing simi
animal pole is positioned to the left. Non-injected oocytes exposed to the antibodies showed
with cRNA coding for the indicated receptor, number indicates the amino acids removed, (−
lane was loaded with membranes from 6 oocytes.assess the location and relative abundance of the receptors. Brieﬂy,
oocytes were incubated in Barth's media with albumin 5% and FBS
10%, for 30 min at room temperature, to block unspeciﬁc binding.
After that, the oocytes were incubated overnight (16 °C) in Barth's
with anti-GABA ρ1 (0.8 μg/ml, Santa Cruz Biotechnology, Santa Cruz,
CA). After washout, the oocytes were incubated in Alexa Fluor 568
goat anti-mouse antibody (2 μg/ml, Invitrogen) for 2 h at room
temperature. Non-injected oocytes were used as speciﬁcity control for
the antibodies. The oocytes were then immediately observed in the
confocal microscope using a Plan-Neoﬂuar 10×/0.3 objective. Finally,
to study the actual translation of the wt receptor and mutants,
Western blots were performed on whole membrane preparations of
injected oocytes, as previously described [18].3. Results
3.1. General properties of hGABA ρ1 and mutations
Deletion mutants whose signal peptide, TM3 or the whole TM4, or
a signiﬁcant part of it, were removed failed to produce evident GABA-
gated ion currents (Table 1); although the deletions tagged with GFP
emitted ﬂuorescence diffusely near the plasma membrane. In Fig. 2A
the ﬂuorescence emitted by an oocyte injected with ρ1GFP is
contrasted with that exhibited by 2 deletion mutants that did not
induce GABA-currents (ρ1Y474GFP, Fig. 2B and ρ1M335GFP, Fig. 2C).
The images did not show obvious differences in ﬂuorescence
distribution between oocytes that gave rise to functional GABA
receptors and those that did not. In contrast, the deletion mutants,
where we removed progressively residues of TM4 from the lastere detected between wild type and mutant receptors. D) wt ρ1, E) ρ1Y474X and F)
lar distribution. Images show a single optical section of the oocyte and in all of them the
no signal. Bar=100 μm. G). Western blot of membranes isolated from oocytes injected
) non-injected oocytes. M is for marker (SeeBlue Pre-Stained Standard, Invitrogen). Each
Fig. 3. Membrane currents elicited by the agonists indicated in oocytes expressing
hGABAρ1 or its deletion mutants. Notice that S479X generated the largest currents
while the subsequent mutations elicited progressively smaller currents.
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elicited GABA-currents of various magnitudes and, therefore, we
proceeded to study the electrophysiological properties of those
receptors.
3.2. Deletion mutants reach the plasma membrane
To determine if the deletion mutants that did not generate
functional receptors were able to reach the plasma membrane, we
did immunoﬂuorescence studies using an antibody directed to the
extracellular amino-terminal domain of the receptor. Confocal laser
microscopy revealed that the oocytes injected with different deletions
and exposed to the Alexa Fluor 568 antibody, showed ﬂuorescence
along the plasma membrane, towards the animal pole. For example,
Fig. 2D shows the label in an oocyte injected with the wt GABAρ1 and
Fig. 2E and F that of oocytes injected with ρ1Y474X and ρ1M335X
respectively, which did not generate GABA-currents. Non-injected
oocytes exposed to the antibodies did not show ﬂuorescence. Those
results suggested that the mutant receptors were inserted in the
plasmamembrane, but were unable to assemble properly and gate the
ion-channel. Western blots of whole oocyte membranes conﬁrmed
the presence of the receptors in all the samples of oocyte plasma
membrane that were tested (Fig. 2G).
3.3. Functional properties of the deletion mutants
All themutants having serial deletions of amino acids spanning the
last four residues generated GABA-currents, and responded also to
other agonists with a sequential potency of GABANβ-alaNGlyNTau
(Tables 1 and 2, Figs. 3 and 4). Removal of the last residue (S479)
resulted in receptors that were more sensitive to GABA than the wild
type receptors, and generated the largest currents: about 6 μA vs. 3 μA
for the wild type with 5 μM GABA, a concentration close to the EC50
(Table 1 and Figs. 3 and 4). In contrast the receptors whose four last
amino acids were deleted gave small GABA-currents (about 250 nA
with 5 μM GABA) (Table 1 and Fig. 4). When the last four residues
(S476X-S479X)were removed, the opening and closing kinetics of the
channels changed notably (Fig. 4), from τo=4±1 s to τo=7.5±1 s
and a τc=45.6±2 s to a τc=29.43±1 s for the wt and S476X
respectively (n=12, each). Moreover, and in sharp contrast to the wt
GABAρ1 and all other GABAρ receptors, the GABA-currents generated
by this mutant desensitized in the presence of the agonist (Fig. 4E).
None of the mutants changed the ion selectivity of the channel as
judged by the equilibrium potential, which in all cases ranged from
−24 to−30 mV, suggesting that Cl− is the main ion ﬂowing through
the channel gated by the agonists. Moreover, in all cases the current/
voltage relations were fairly linear, within the potential range
explored (−120 to +40 mV) (data not shown). As is the case forTable 2
Agonists half-maximal responses (EC50 in μM) and Hill number of wt and mutant
receptors. Observe the shift in the neurotransmitter EC50 of the mutants; the largest
deletions had reduced sensitivity to the agonists, except for S479X, that was more
sensitive (wt n=12, each mutant n=16, 4 frogs). Mean±SEM. *Pb0.05, vs. wt
(Student's t-test).
Agonist
(μM)
Receptor
wt S479X F478X I477X S476X
β-alanine 150±1 73.5±3* 740±3 810±3 10,000±2
Hill no. 1.7 1.2 1.2 1.1 1.3
Taurine 4200±2 3600±3* 13,600±3 15,000±2 62,000±2
Hill no. 0.8 2.8 1.6 1.9 1.9
Glycine 5000±3 3800±2* 31,000±2 41,600±1 63,000±3
Hill no. 1.9 1.3 1.6 1.9 1.6
*Pb0.05 vs. wt (Student's t-test).the wt GABAρ receptors, La3+ modulated positively the currents of all
the mutants; with EC50s for GABA between 111 μM and 4.0 mM. The
peculiar characteristics of the S476X receptors were reﬂected also in
their sensitivity to La3+, since they were affected less by La3+
(Table 3). On the other hand, the negative modulator Zn2+ [29]
reversibly blocked the currents generated by GABA, β-Ala, Gly and Tau
from all the tested mutants. The IC50s to this metal ranged from 10 μM
to 2.8 mM, being S479X the most sensitive (Table 4). We also
examined the effect of the TPMPA, a selective GABAρ antagonist [19].
This compound potently and reversibly blocked the currents induced
by the agonists in all mutant receptors. The S479X showed major
sensitivity to the TPMPA, than the other receptors, even the wt. In the
case of S476X, the TPMPA concentration required for half-maximum
inhibition (IC50) was more than 100 μM (data not shown).
4. Discussion
An attempt was made here to determine the functional relevance
of the residues that form the C-terminus of the GABAρ1 receptor. Very
little was known about the roles played by the fourth transmembrane
segment and the short carboxy-end of ionotropic GABAρ-receptors on
the function of the receptors. We therefore conducted this study to
assist any future and more detailed determination of structure/
function relations of this fairly unique receptor.
Few studies have been made on the C-terminus of human ion
channels. It has been demonstrated recently that the C-terminus plays
an important role in the formation of functional h5-HT3A receptors
[20]. Moreover, the structure of the heteromeric nicotinic Ach
receptor suggests that, whether the channel is open or closed, the
TM4 segment physically contacts the TM1 and TM3 segments [21]
and, considering the well conserved amino acid sequence between
the nACh and GABAρ1 receptors, it can be assumed that this will also
be true for the homopentameric human receptor used in this study.
Thus, deleting the whole or part of theα-helix of TM4will predictably
destabilize the bundle arrangement formed by the TM segments of
each subunit. This prediction was partially fulﬁlled by our results, but
unexpectedly we found that the GABAρ1 receptors in which we
removed the last amino acid (S479) and up to three more of the
residues that form part of the α-helix of TM4 (F478, I477, S476), still
generated GABA-currents. Interestingly, the mutant which had only
the last amino acid removed (S479X) was the most sensitive to all the
agonists tested (cf Tables 1 and 2). The sequential removal of the next
amino acids produced a gradual loss of receptor sensitivity; and some
channel kinetics were also altered, indicating that the structure was
further affected. Introduction of a stop codon after W475, as well as
further deletions extending towards the N-end, resulted in non-
Fig. 4.Neurotransmitter-gated ion currents. Sample traces generated by near EC50 concentrations of GABA (5 μM), β-ala (200 μM), glycine (7 mM) and taurine (5 mM) in the oocytes
expressing hGABA ρ1 (A) or the indicated deletionmutant (B–E). The horizontal bar indicates the time of application of the agonist. Note the largest currents generated by S479X (B),
and the smaller currents of the subsequent deletions (F478X, I477X and S476X.)
Table 4
Effect of zinc. The Zn2+ blocking on the receptors activated by the corresponding EC50 of
GABA (3.4 μM), β-ala (150 μM), Tau (4.2 mM) and Gly (4.2 mM). wt n=11, each
mutant n=18, 4 frogs. Mean±SEM.
Agonist
(mV)
Receptor
wt S479X F478X I477X S476X
GABA 22.6±3 9.9±4 30±6 50±5 623±3
Hill no. 1.9 1.1 1.3 1.2 1.9
β-alanine 26.7±2 13.2±6 43.7±4 196±3 631±5
Hill no. 0.8 1.0 1.7 1.3 2.0
Taurine 30.8±3 17.4±4 92.5±4 152±6 1300±7
Hill no. 1.2 0.7 1.3 1.5 1.7
Glycine 57.4±4 25.7±5 111±6 211±4 2800±5
Hill no. 1.2 0.9 1.7 1.4 1.2
1006 J.M. Reyes-Ruiz et al. / Biochimica et Biophysica Acta 1798 (2010) 1002–1007functional receptors, although they were still localized in the plasma
membrane. Further experiments will be necessary to probe if the
ethanol sensitivity of the GABAρ receptor has been modiﬁed, such as
is the case for the glycine receptor in which several residues of the
TM4 are important to form a water-accessible cavity important for
alcohol binding [22].
All the functional deletion mutants studied were efﬁciently
activated by β-ala, Gly and Tau; and the currents generated by
those agonists were all effectively blocked by TPMPA (not shown) and
zinc. This is consistent with the presumed mechanism of action of
both molecules, since TPMPA is known to compete for the agonist
binding site [19,23,24], and zinc binds to residue H156 present in the
extracellular domain of the receptor [10], and both sites were
unaffected in the functional deletions. La3+ acts on GABAA receptors
at a site different from the sites of action of barbiturates, benzodia-
zepines, picrotoxin, or zinc [25–28]. It positively modulated iono-
tropic GABAρ1 receptors [29], and it also potentiated the currents of
all the functional deletion mutants, in agreement with a presumed
direct lanthanide–receptor interaction at a site capable of allosteri-
cally modulating channel properties [30].
All ionotropic GABA receptors, including the GABAρ1, have a
predicted signal sequence that spans 16–24 residues of the amino-endTable 3
Effect of lanthanum. Positive modulation of lanthanum on receptors activated by the
corresponding EC50 for each agonist [GABA (3.4 μM), β-ala (150 μM), Tau (4.2 mM) and
Gly (4.2 mM)]. wt n=12, each mutant=12–14, 4 different frogs. Mean±SEM.
Agonist
(μM)
Receptor
wt S479X F478X I477X S476X
GABA 111±3 90±2 174±2 205±3 4000±4
Hill no. 0.7 1.1 1.9 1.9 1.2
β-alanine 130±2 97±4 151±3 217±4 5600±3
Hill no. 1.2 0.7 1.3 1.9 1.6
Taurine 157±3 125±3 195±1 245±4 45,000±2
Hill no. 1.2 0.9 1.73 1.9 1.1
Glycine 198±3 162±1 221±3 300±1 51,000±3
Hill no. 1.0 0.7 1.7 1.7 1.4of the protein [6]. Since experimental analysis of this region has not
been extensible we decided to see if GABAρ1 was properly targeted to
the membrane after deleting this hydrophobic tract of residues. Three
independent cRNAs were injected and all failed to produce receptors
capable of generating GABA-currents, thus conﬁrming the fundamen-
tal role of the signal peptide in this family of receptors. However, the
precise role of this signal sequence in the biogenesis and proper
membrane targeting of the receptor still remains to be determined.
We still have to study how the structural modiﬁcation of the C-
terminus impacts the gating of the ion-channel. The altered activation
kinetics of the receptors that lack one or four residues, and the higher
sensitivity to GABA of the mutant that lacks only one residue are
worth studying at the single channel level to see if their characteristics
have been altered. All these will be very important in the future, when
the atomic structure of this family of receptors is determined.Acknowledgements
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